Can I read CAR-T Cell Therapy for Refractory SLE on EtoBox?

CAR-T Cell Therapy for Refractory SLE by Don Sunil is a document available to read on EtoBox.

What is CAR-T Cell Therapy for Refractory SLE about?

A phase 1 trial investigated the safety and efficacy of co-infusing CD19-targeting and BCMA-targeting CAR-T cells in patients with treatment-refractory systemic lupus erythematosus (SLE). The results showed no dose-limiting toxicities and significant clinical improvement, with 80% of patients achieving remission criteria within 12 weeks. This study suggests that dual CAR-T cell therapy may be a promising treatment strategy for refractory SLE, warranting further research.

Author

Don Sunil

Language

EN